Acelrx pharmaceuticals announces presentation of a large cohort of complex plastic surgery procedures performed with dsuvia at plastic surgery the meeting 2022

The study of 324 complex plastic surgery procedures demonstrated many benefits of using dsuvia for analgesia, including avoiding the need for general anesthesia hayward, calif. , oct. 31, 2022 /prnewswire/ -- acelrx pharmaceuticals, inc. (nasdaq: acrx), (acelrx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that an abstract, entitled, "experience in complex outpatient plastic surgery procedures using sufentanil sublingual tablets" was presented on friday, october 28 th by jeffrey deweese, m.d.
ACRX Ratings Summary
ACRX Quant Ranking